Krsnaa Diagnostics Limited has informed the Exchange regarding a press release dated August 11, 2025, titled "Press Release Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025.".
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krsnaa Diagnostics posted strong Q1FY26 results with revenue of ₹1,930 million, up 13% year-on-year. EBITDA grew 19% YoY to ₹524 million with margins expanding to 27%, while net profit rose 15% YoY to ₹205 million and EPS came in at ₹6.25. For full-year FY25, revenue grew 16% to ₹7,172 million with EBITDA jumping 34% to ₹1,958 million and PAT up 37% to ₹776 million. A major highlight was the company winning the Rajasthan pathology services contract under the National Health Mission, under which it will set up 42 Mother Labs, 135 Satellite Labs, and over 1,300 collection centers. The company also added 75 new centers in the quarter and reported breakout retail growth, now spanning 2,414 locations across four states.
The Rajasthan PPP win is a significant large-scale order that strengthens long-term revenue visibility and cements Krsnaa's leadership in public-private diagnostics partnerships. Consistent double-digit growth across revenue, EBITDA, and PAT, combined with margin expansion, signals strong operational momentum likely to be viewed positively by investors.